Treatment
Ruxolitinib clinical trials
We’re tracking 103 recruiting studies that include Ruxolitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07794514Recruiting
Comparing two drugs for liver graft-versus-host disease
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
Hangzhou, ZhejiangAges 12 years+ - NCT05280509RecruitingPhase 1/Phase 2
Test TL-895 plus ruxolitinib for myelofibrosis
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Birmingham, AlabamaAges 18 years+ - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT06479135RecruitingPhase 3
Study of new drug added to ruxolitinib for myelofibrosis
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Birmingham, AlabamaAges 18 years+ - NCT07357727RecruitingPhase 3
Study of Pelabresib and Ruxolitinib for Myelofibrosis
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Denver, ColoradoAges 18 years+ - NCT05817955RecruitingPhase 2
Azacitidine plus ruxolitinib for higher-risk MDS/MPN
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Nanjing, JiangsuAges 18–80 - NCT03110822RecruitingPhase 1
Ruxolitinib, steroids, and lenalidomide for hard-to-treat myeloma
This Phase 1 trial tests a combination of ruxolitinib plus steroids and lenalidomide in people with relapsed or refractory multiple myeloma. It’s designed for patients who have had at least two prior treatment options and whose myeloma is getting worse or not responding.
Alhambra, CaliforniaAges 18 years+ - NCT06199427RecruitingPhase 2
Preventing graft-versus-host disease after stem cell transplant for immune disorders
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
MoscowAges birth–21 years - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT07783412RecruitingPhase 2
Topical ruxolitinib cream for pyoderma gangrenosum ulcers
This study tests a cream called ruxolitinib to treat pyoderma gangrenosum, a painful skin condition that causes deep ulcers. The cream is applied directly to the ulcer and may help it heal without the side effects of pills or injections.
Portland, OregonAges 18–99 - NCT07673640Recruiting
Ruxolitinib cream with steroids for active vitiligo on face
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
Shenzhen, GuangdongAges 12 years+ - NCT06719024RecruitingPhase 2/Phase 3
Ruxolitinib cream for vitiligo on face and neck
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
Hong KongAges 18–85 - NCT07548983RecruitingPhase 1
Maintenance therapy after stem cell transplant for AML
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Portland, OregonAges 18 years+ - NCT07521046RecruitingPhase 1
Adding interferon to ruxolitinib for myelofibrosis
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
Salt Lake City, UtahAges 18 years+ - NCT06225310RecruitingPhase 1
New combo for relapsed/refractory multiple myeloma
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
West Hollywood, CaliforniaAges Any age - NCT07464951RecruitingPhase 1
CART123 cells with or without ruxolitinib for AML
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Philadelphia, PennsylvaniaAges birth–29 years - NCT07424222RecruitingPhase 1
Ruxolitinib for a serious immune reaction after CAR T therapy
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Baltimore, MarylandAges 18–99 - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT06261021RecruitingPhase 2
Ruxolitinib cream for discoid lupus study
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
Fredericton, New BrunswickAges 18 years+ - NCT07278856RecruitingPhase 1
Ruxolitinib plus CHOP for untreated T-follicular helper cell lymphoma
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75
What Ruxolitinib is being studied for
Conditions with recruiting Ruxolitinib studies.
Common questions
- Are there clinical trials studying Ruxolitinib?
- Yes. Clin2 currently lists 103 recruiting studies that include Ruxolitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ruxolitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ruxolitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ruxolitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.